{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:27:07Z","timestamp":1784708827171,"version":"3.55.0"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Reviews in Medical Virology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several phase\u20101 clinical trials have been performed to evaluate the safety and efficacy of candidate anti\u2010Zika vaccines. In this systematic review, we systematically evaluated the safety and immunogenicity of candidate vaccines, which would aid researchers in formulating an effective vaccination strategy for phase\u20102 trials based on current evidence. A literature search was conducted using the electronic databases MEDLINE through Pubmed, Web of Science, and Cochrane Database for relevant studies on candidate anti\u2010zika vaccines. Studies on animal models were excluded from our study. Healthy individuals who were administered candidate Zika vaccines to evaluate the immune response and adverse events (AEs) compared to placebo were considered. Data were extracted, tabulated, and analysed using Microsoft Excel, while the risk of bias plots were generated using tidyverse and Robvis packages in R\u2010studio. A total of five phase\u20101 clinical trials were included in our analysis comprising of studies on inactivated, viral vector, and DNA vaccines. Immunogenicity ranged from 10% to 100% after vaccination with the lowest seroconversion rate (10%) and geometric mean titre (GMT) (6.3; 95% confidence interval (CI):3.7\u201310.8) observed among recipients of single\u2010dose inactivated anti\u2010zika vaccine (ZPIV). For DNA vaccines, the seroconversion rate ranged from 60% to 100% with the highest seroconversion rate (100%) and GMT (2871; 95% CI:705.3\u201311688) observed among recipients of three shots of high dose GLS\u20105700 vaccine. For viral vector vaccine (Ad26.ZIKV.001) seroconversion rate (100%) and GMT peaked after two shots with both low and high\u2010dose vaccines. In all those studies AEs were mostly local including injection site pain, erythema, and itching. The most common systemic AEs included fever, myalgia, nausea, and fatigue. In phase\u20101 clinical trials, all candidate vaccines were found to be highly immunogenic and relatively safe, especially when administered in higher doses and with the help of needle\u2010free devices.<\/jats:p>","DOI":"10.1002\/rmv.2385","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T07:44:31Z","timestamp":1660981471000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety and immunogenicity of Zika virus vaccine: A\u00a0systematic review of clinical trials"],"prefix":"10.1002","volume":"33","author":[{"given":"Mahmuda","family":"Yeasmin","sequence":"first","affiliation":[{"name":"Department of Virology National Institute of Laboratory Medicine and Referral Center  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-9144","authenticated-orcid":false,"given":"Md. Maruf Ahmed","family":"Molla","sequence":"additional","affiliation":[{"name":"Department of Virology National Institute of Laboratory Medicine and Referral Center  Dhaka Bangladesh"},{"name":"College of Graduate Studies State University of New York Upstate Medical University  Syracuse New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M. Abdullah Al","family":"Masud","sequence":"additional","affiliation":[{"name":"Department of Microbiology Faculty of Biological Sciences University of Chittagong  Chattogram Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Saif\u2010Ur\u2010Rahman","sequence":"additional","affiliation":[{"name":"Health Systems and Population Studies Division icddr, b  Dhaka Bangladesh"},{"name":"Evidence Synthesis Ireland and Cochrane Ireland  Galway Ireland"},{"name":"College of Medicine Nursing and Health Sciences National University of Ireland  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035\u20109203(52)90042\u20104"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1590\/0074\u201002760150192"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.03.010"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix515"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1705.101939"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020266"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00014\u201016"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix464"},{"key":"e_1_2_14_10_1","volume-title":"Efficacy of Vaccine Candidates against Zika Infection and Congenital Zika Syndrome: A Systematic Review and Meta\u2010Analysis","author":"Lund H","year":"2021"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.52225\/narraj.v1i1.e32"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v1i3.57"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1229"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060410"},{"key":"e_1_2_14_15_1","article-title":"Safety and immunogenicity of anti\u2010Zika virus DNA vaccine","author":"Tebas P","year":"2017","journal-title":"N. Engl J Med"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33105-7"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(17)33106\u20109"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473\u20103099(20)30085\u20102"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/m20\u20105306"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature18952"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4163"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1730657"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00147"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v2i1.71"},{"key":"e_1_2_14_25_1","unstructured":"World Health Organization.WHO Lists Additional COVID\u201019 Vaccine for Emergency Use and Issues Interim Policy Recommendations;2021. Retrieved from.https:\/\/www.who.int\/news\/item\/07\u201005\u20102021\u2010who\u2010lists\u2010additional\u2010covid\u201019\u2010vaccine\u2010for\u2010emergency\u2010use\u2010and\u2010issues\u2010interim\u2010policy\u2010recommendations"}],"container-title":["Reviews in Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.2385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rmv.2385","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.2385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T16:51:53Z","timestamp":1706892713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rmv.2385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/rmv.2385"],"URL":"https:\/\/doi.org\/10.1002\/rmv.2385","archive":["Portico"],"relation":{},"ISSN":["1052-9276","1099-1654"],"issn-type":[{"value":"1052-9276","type":"print"},{"value":"1099-1654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"2022-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2385"}}